Versuchen GOLD - Frei
Accelerated Reliance on Digital Animal Replacement Tech
Bio Spectrum
|August 2025
While Europe is talking about non-animal replacement tests to be used for drug development and research purposes, US FDA is acting upon it with a detailed roadmap aimed at rapidly reducing animal testing in preclinical safety assessments. These developments clearly provide huge opportunities for global companies that are developing alternative methods such as organoids, 3D bioprinting, digital animal replacement technology, computer simulation, to name a few. But where does India stand in this regard, and how skilled are we to make this shift?
-
On April 29, the National Institutes of Health (NIH) in the US announced the adoption of a new initiative to expand innovative, human-based science while reducing animal use in research. In particular, the NIH intends to establish the Office of Research Innovation, Validation, and Application (ORIVA) to develop, validate, and scale the use of non-animal approaches across the agency’s biomedical research portfolio and serve as a hub for interagency coordination and regulatory translation for public health protection.
Developing and using cutting-edge non-animal research models very well aligns with the US Food and Drug Administration’s (FDA) recent initiative to reduce testing in animals.
Simultaneously, the European Medicines Agency (EMA) has released a revised draft paper that outlines non-animal replacement tests manufacturers can use to eliminate the use of animals in pharmaceutical testing. Further, the European Commission has confirmed plans to finalise its ‘Save Cruelty Free Cosmetics’ roadmap by early 2026, setting the stage for a gradual transition toward non-animal testing in chemical safety assessments.Where does India stand in this scenario? Although an amendment to the New Drugs and Clinical Trial Rules (2023), passed by the Government of India in 2023, aimed to replace the use of animals in research, especially in drug testing, not much progress has been made so far. Indian regulatory bodies are still working out ways to strengthen the use of non-animal testing methods in laboratories across the country, as they are aware that completely eliminating animal models may not be a feasible process.
Diese Geschichte stammt aus der August 2025-Ausgabe von Bio Spectrum.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Bio Spectrum
Bio Spectrum
Building Breakthrough Medical Devices
Dr Ria Khurana founded RNT Health Insights, a Chandigarh-based healthtech startup specialising in Al-assisted diagnostic solutions for the accurate detection of pathologies during endoscopic procedures, in 2022 along with Dr Tanmaya Gulati.
2 mins
January 2026
Bio Spectrum
Bridging classical epidemiology with modern science
A physician scientist with a MBBS from Lady Hardinge Medical College, (University of Delhi), a post-graduation in Paediatrics and a PhD from All India Institute of Medical Sciences (AIIMS), New Delhi, Prof.Shinjini Bhatnagar served as Professor of Eminence at Translational Health Science and Technology Institute (THSTI) until February 2023 and was subsequently appointed Distinguished Professor at THSTI until May 2025.
2 mins
January 2026
Bio Spectrum
"AI, Automation & Analytics: A new era of modern microbiology testing!"
Pharmaceutical manufacturing is undergoing a paradigm shift.
4 mins
January 2026
Bio Spectrum
The CRISPR Moment
CRISPR (clustered regularly interspaced short palindromic repeats) technology is ushering in a new era of gene and cell therapy, offering more precision and potential for treating genetic disorders, cancer, and infectious diseases.
2 mins
January 2026
Bio Spectrum
Leveraging Microfluidic Technology for mRNA-LNP Manufacturing
Over the past five years, messenger RNA (mRNA) therapeutics have evolved from experimental concepts into lifesaving medicines.
2 mins
January 2026
Bio Spectrum
Demonstrating India's Vaccine Capabilities
Havisure is India's first and only indigenously developed Hepatitis A vaccine, to address one of the country's most persistent public health challengeswidespread Hepatitis A infections caused by inadequate sanitation and contaminated food and water.
2 mins
January 2026
Bio Spectrum
Inspiring Future Generations
A PhD in molecular biology from the University of Cambridge, UK, Prof. Gaiti Hasan is a Distinguished Fellow at the National Centre for Biological Sciences (NCBS), Bengaluru.
2 mins
January 2026
Bio Spectrum
A Landmark for India's Antibiotic Innovation
After three decades of research and hard work, India has led the way with the creation of Nafithromycin, the country's first indigenous antibiotic.
2 mins
January 2026
Bio Spectrum
"Future vaccine innovation will be integration of R&D, regulatory support and manufacturing”
TechInvention Lifecare Limited, a vaccine focused biotechnology company headquartered in Mumbai, is recognised for its innovative contributions to global healthcare.
4 mins
January 2026
Bio Spectrum
Telangana: Building India's Most Credible Life Sciences Ecosystem
Telangana's recognition as BioSpectrum India's Best Performing State in Life Sciences 2025 is a timely validation of the direction the state has taken in recent years-one anchored in execution, responsiveness, and a clear understanding of where global life sciences value chains are headed.
4 mins
January 2026
Listen
Translate
Change font size

